Meeting
2021 ASCO Annual Meeting
Patients with steroid-refractory toxicity following immune checkpoint inhibitors: Frequent hospitalizations and long duration of illness.
Authors
Mia Bothwell
Massachusetts General Hospital, Boston, MA
Mia Bothwell , Aaron Cheng , Leyre Zubiri , Meghan Mooradian , Yevgeniy R. Semenov , Gayle C. Blouin , Erica Tavares , Jennifer Hutchinson , Leila Rostamnjad , Monica Jackson , Kerry Lynn Reynolds
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Developmental Therapeutics—Immunotherapy
Track
Developmental Therapeutics—Immunotherapy
Sub Track
Other IO-Related Topics
Citation
J Clin Oncol 39, 2021 (suppl 15; abstr 2655)
DOI
10.1200/JCO.2021.39.15_suppl.2655
Abstract #
2655
Poster Bd #
Online Only
Abstract Disclosures
Similar Posters
Poster
2023 ASCO Annual Meeting
Risk of immune-related adverse events (irAE) with immune checkpoint inhibitors (ICI) in patients (pts) with family history (FH) of autoimmune disease (AID).
First Author: Piyush Grover
Poster
2023 ASCO Annual Meeting
Frequency of delayed immune-related adverse events (irAEs) in hospitalized patients treated with immune checkpoint inhibitors (ICIs).
First Author: Sienna Durbin
Poster
2023 ASCO Annual Meeting
Development of a novel immune-related toxicity grading system for predicting outcomes in patients with solid tumours treated with immune checkpoint inhibitors (ICI).
First Author: Matthaios Kapiris
Poster
2023 ASCO Annual Meeting
Association between severe adverse event management and overall survival in patients treated with immune checkpoint inhibitor with advanced non–small-cell lung cancer.
First Author: Jarushka Naidoo